Believe it or not, medication names are intended to be easy to remember and descriptive of the function they serve in the body.
While pills come in many shapes and sizes, they all eventually reach your bloodstream and travel throughout your body.
Vadim Sazhniev/iStock via Getty Images
An infectious disease doctor discusses the use, benefits and availability of a drug to prevent severe COVID-19.
Pan-assay interference compounds, or PAINS, often come up as false positives when researchers screen for potential drug candidates.
unol/iStock via Getty Images Plus
Drug repurposing can redeem failed treatments and squeeze out new uses from others. But many pharmaceutical companies are hesitant to retool existing drugs without a high return on investment.
Changes in the latest federal budget will mostly affect people who need multiple medicines throughout the year, perhaps for chronic disease. But there are other ways to reduce drug costs.
It’s easy to blame COVID. But Australia has suffered medicine shortages for years. The pandemic has only highlighted the problem. Here’s what we could do to better avoid shortages in the first place.
The majority of drug failures are attributed to lack of clinical efficacy and high toxicity.
Andrew Brookes/Image Source via Getty Images
Drug development is a long and costly process that often ends in failure. Improving the way potential drug candidates are optimized could help boost success rates.
Generic drug names are assigned at the global level by the World Health Organization in conjunction with national naming authorities.
(Shutterstock)
Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
Paxlovid is one potential COVID drug for use at home. The idea is these can potentially be prescribed at the first sign of infection to prevent serious illness and death.
A new study suggests the market alone will not deter or punish pharmaceutical companies whose products turn out to have adverse effects after they have been approved.
Non-intoxicating cannabis products are safe and well tolerated by those who use them, so why not lower the clinical threshold for their manufacture and sale?